Patents
Literature
54 results about "Isotype" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In immunology, the immunoglobulin (Ig) isotype (class) is encoded by the constant region segments of the immunoglobulin gene which form the Fc (Fragment crystallizable region) portion and the lower segment of the Fab (Fragment antigen-binding) portion of an antibody. The expression of a specific isotype determines the function of an antibody via the specific binding to Fc receptor molecules on different immune effector cells. Isotype expression reflects the maturation stage of a B cell. Naive B cells express IgM and IgD isotypes with unmutated variable genes, which are produced from the same initial transcript following alternative splicing. Expression of other antibody isotypes (IgD, IgM IgG1-4, IgA1-2, IgE) occurs via a process of class-switch recombination (CSR) after antigen exposure. Class-switching is mediated by the AID (activation-induced cytidine deaminase) enzyme and only occurs after the B cell binds an antigen through its B cell receptor, and is further activated through interaction with a T helper cell.
Chimeric antigen receptors against multiple HLA-g isoforms
PendingUS20260070988A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyWhite blood cellAntigen receptors
The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G β2M-free or β2M-associated immunosuppressive isoforms respectively.
Owner:INVECTYS SA
Hepatocyte nuclear factor four alpha antisense RNA 1 targeting polynucleotide and method of use and treatment thereof
The present invention comprises a pharmaceutic composition comprising one or more hepatocyte nuclear factor four alpha antisense RNA 1 (HNF4A-AS1) targeting polynucleotides, wherein the one or more HNF4A-AS1 targeting polynucleotides is capable of repressing HNF4A-AS1 in a subject resulting in upregulation of HNF4A expression and / or increasing HNF4A P1:P2 isoform ratio in the subject. The present invention also provides a method of treatment of a HNF4A-associated disease in a subject comprising the step of administering a therapeutically effective amount of the pharmaceutical composition comprising one or more HNF4A- AS1 targeting polynucleotides of the present invention. The present invention also provides a method of downregulating HNF4A P2 isoform expression in a subject comprising the step of repressing HNF4A-AS1 in the subject.
Owner:GENECO PTY LTD
Composition comprising an IgE antibody
ActiveUS12606617B2Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsPharmacy medicineIntravenous gammaglobulin
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.
Owner:KINGS COLLEGE LONDON
MASP isotypes as inhibitors of complement activation
This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.
Owner:OMEROS CORP
Natural killer cell cement
PendingCN120787237AAntibody mimetics/scaffoldsPeptide/protein ingredientsCancer cellNatural Killer Cell Inhibitory Receptors
The invention relates to methods and materials for treating cancer. For example, provided herein are cell adhesives capable of binding to natural killer (NK) cells and cancer cells. In some cases, the cell binding agents provided herein may comprise a first antigen binding domain capable of binding to a NK cell group 2 isoform C (NKG2C) polypeptide and a second antigen binding domain capable of binding to a cancer cell surface polypeptide. In some cases, one or more cell binding agents provided herein may be administered to a mammal (e.g., a human) having a cancer (e.g., a leukemia such as acute myelogenous leukemia (AML)) to treat cancer.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA +1
Bispecific antibodies and constructs for lysosomal targeting degradation and methods of use thereof
PendingUS20260055194A1Immunoglobulins against cell receptors/antigens/surface-determinantsLysosomal targetingBispecific antibody
Provided herein are antigen-binding proteins (ABPs) that selectively bind to M6PR and its isoforms and homologs, and compositions comprising the ABPs. Also provided herein are bispecific antigen-binding proteins (ABPs) that selectively bind to internalizing receptors, and a soluble target molecule or cell surface target molecule and its isoforms and homologs, and compositions comprising the ABPs.
Owner:LYCIA THERAPEUTICS INC
P53 isoform variant for diagnosing cancer
PendingUS20260092923A1Immunoglobulins against animals/humansDisease diagnosisAntiendomysial antibodiesDeletion mutation
A method of collecting data for diagnosing cancer, determining an onset risk, determining a malignancy grade, and / or predicting a prognosis of cancer according to the present disclosure includes the steps of bringing a sample derived from a subject into contact with tumor-associated antigens to cause an antigen-antibody reaction; measuring an amount of anti-p53 antibody, in the sample, that specifically binds to any of the tumor-associated antigens; and comparing the measured amount of the anti-p53 antibody with a predetermined reference level of the anti-p53 antibody against the tumor-associated antigens. The tumor-associated antigens include one or more p53 isoform variants consisting of amino acid sequences having a mutation in an amino acid sequence of any one of SEQ ID NOs: 1 to 3, and the mutation includes any one of an N-terminal deletion mutation, a C-terminal deletion mutation, and both the N-terminal deletion and the C-terminal deletion mutation.
Owner:TUNING FORK BIO INC
CNOT9 binding RNA degraders
The present invention includes compounds and compositions, and methods of use thereof for modulating an RNA transcript, or a precursor, isoform, fragment, or mutant thereof by degradation of the RNA transcript via recruitment or binding of one or more decay factors (e.g., an RNA binding protein).
Owner:ARRAKIS THERAPEUTICS INC
ANTIBODIES SELECTIVE TO 4Ig ISOFORM OF B7-H3 AND METHODS OF USE THEREOF
PendingCN120787161APolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen bindingInflammation
Provided herein are antibodies and antigen-binding portions thereof that specifically bind to the 4Ig isoform of B7 homolog 3 protein (B7-H3), various compositions of such antibodies or antigen-binding portions thereof, and recombinant nucleic acids encoding the antibodies and antigen-binding portions thereof. Also provided are methods of using the antibodies or antigen-binding portions thereof in the treatment and diagnosis of cancer or inflammation.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
PCT designated stageWO2026035843A3Genetically modified cellsImmunoglobulins against virusesImmunoglobulin heavy chainHuman cell
Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC
Anti-HLA-dr igm isotype monoclonal antibody potentiating the activity of Anti-CD20 igg1 or igm isotype antibodies
PCT designated stageWO2025253079A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesMalignancy
The present invention relates to a novel anti-HLA-DR IgM isotype monoclonal antibody and to the use thereof alone or in addition to anti-CD20 IgG1 or IgM isotype antibodies, in the treatment of B-phenotype lymphoid hemopathies, and in particular of non-Hodgkin lymphoma B, chronic lymphocytic leukemia (CLL) and B-cell malignant lymphoid hemopathies in general.
Owner:CENT NAT DE LA RECH SCI (C N R S) +5
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
PendingUS20260123608A1Genetically modified cellsImmunoglobulins against virusesImmunoglobulin heavy chainConstant region
Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC
Tumor-selective e1a and e1b mutants
Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
Owner:RGT UNIV OF CALIFORNIA
Sirna for silencing a new isoform of the mitochondrial chaperone trap1
A siRNA characterised by having a sequence selected from the group comprised of: - SEQ ID NO. 1 : 5 ' CUCUUUCCCUUGAAUAAGC 3 '; - SEQ ID NO. 2 : 5 ' UGAUUCCCAAAGCUCACAG 3 '; and - a sequence including at least 16 contiguous nucleotides differing by no more than 3 nucleotides from SEQ ID No. 1 or SEQ ID No. 2, to silence TRAPl-low SEQ ID N°3. The use of the 5 'UTR SEQ ID N°4 region of the TRAPl-low transcript SEQ ID N°3 or a portion of that 5 'UTR region selected from the group comprised of: - the SEQ ID No. 6 portion of said 5 ' UTR region comprising nucleotide positions 1 through 644; - a portion of said region 5 ' UTR comprising the portion of SEQ ID No. 6 extended by a predetermined number of nucleotide positions beyond nucleotide position 644 along said region 5 'UTR.
Owner:C R O B CENT DI RIFERIMENTO ONCOLOGICO DELLA BASILICATA INST DI RICOVERO E CURA A CARATTERE SCIO +1
Compositions and methods for immune cell modulation in adoptive cell therapy
PendingUS20260034216A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAdoptive cellular therapyWhite blood cell
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin-2-inducible T cell kinase (ITK), delta isoform of phosphoinositide 3-kinase (PI3Kδ), helios, blimp1, SOCS1, GATA3, IL-10, STAT3, TOX, CD25, foxp3, Ezh2, TGF-beta Receptor II, LAG-3, PD-1, TNF-alpha, or combinations thereof. The immune cells are optionally depleted of CD8+ T cells by about 10-fold or greater relative to un-depleted leukocytes.
Owner:JOHNS HOPKINS UNIVERSITY +1
New splice variant isoform of VEGF
PendingUS20250346642A1Peptide/protein ingredientsMicrobiological testing/measurementLymphatic vesselLymphangiogenesis
The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:1, preferably is VEGF222 / NF and consists of SEQ ID NO:1.
Owner:CENT NAT DE LA RECH SCI (C N R S) +2
Anti-soluble interleukin-7 receptor antibody therapy to treat autoimmune diseases
PendingUS20260098099A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody SuppressionImmunologic disorders
Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Nucleic acid agents modulating fas isoforms
The present disclosure relates to manipulation of splicing of the Fas (tumor necrosis factor (TNF) receptor superfamily, member 6) gene in non-naïve cell of the T lineage for enhanced skipping of exon 6. The manipulated non-naïve cells predominantly express a soluble form of Fas (sFas) and display reduced expression of the membranal Fas (mFas), increased cytokine secretion, increased expression of activation markers, increased cell survival, increased cytotoxicity, and / or reduced expression of exhaustion markers. The present disclosure further provides specific splicing modulatory agents comprising gene editing systems and / or splice switching antisense oligonucleotide (SSO), methods and therapeutic uses thereof.
Owner:HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
ActiveUS12540197B2Immunoglobulins against blood coagulation factorsOrganic active ingredientsAntiendomysial antibodiesAntibody conjugate
The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.
Owner:SUTRO BIOPHARMA INC
Isoform-selective Anti-TGF-beta antibodies and methods of use
The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2 / 3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.
Owner:GENENTECH INC
Novel protein isoforms and uses
The present disclosure provides novel protein isoforms, including transmembrane proteins, encoded by variant transcripts generated from non-canonical splicing, and corresponding peptides, nucleic acids, vaccines, antibodies and immune cells that can be used in diagnosis and therapy.
Owner:INSTITUT CURIE +2
Genetic reprogramming by re-expression of ESE3 / EHF for the treatment of advanced prostate cancer
PCT designated stageWO2026033361A1Organic active ingredientsPeptide/protein ingredientsImmunotherapeutic agentOncology
The present invention relates to a nucleic acid sequence encoding the transcription factor ESE3 / EHF or an isoform thereof, for use in the treatment of a cancer in a patient in need thereof and can be a mRNA or a DNA, in particular for use in the treatment of prostate cancer. The invention also relates to a plasmid, a viral vector or a pharmaceutical composition comprising, such nucleic acid sequence. In particular, the present invention is based on the use of plasmid DNA coding the full-length sequence of the gene ESE3 / EHF and to the use of in vitro transcribed (IVT) mRNA of ESE3 / EHF as gene therapy in aggressive prostate cancerESE3 / EHF is a transcription factor that is expressed in normal prostate but is lost in prostate tumors, particularly during the progression from indolent to aggressive tumors. The aim is to replace the ESE3 / EHF transcription factor using gene therapy approaches at the time the gene is reduced or lost. The invention also relates to the use of ESE3 / EHF replacement in combination therapy with androgen deprivation therapy (ADT), the standard treatment for metastatic prostate cancer, and other therapies, such as androgen receptor signalling inhibitors (ARSI), chemotherapeutics, molecular-targeted therapeutics, and immunotherapeutics.
Owner:FOND PER LINST ONCOLOGICO DI RICERCA (IOR)
Alternatively spliced isoform in cancer and methods of use thereof
PendingUS20250320562A1Microbiological testing/measurementDisease diagnosisSplice isoformsCancer research
The present disclosure is directed to methods of predicting resistance to a purine analog by detecting the presence of a NT5ex4a isoform. Further provided herein are methods of treating the subject with resistance by administering a purine biosynthesis inhibitor.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Monoclonal mouse antibodies against human estrogen receptor, human progesterone receptor, human ki-67, and human p53
PCT designated stageWO2026104883A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenPR - Progesterone receptor
Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.
Owner:FARZAM MOHAMMAD
Methods for assessing cardiac mesothelial cell distribution based on immunofluorescence images
ActiveCN121280349BGet a comprehensive understanding of dyeing performanceImprove recognition accuracyImage analysisAcquiring/recognising microscopic objectsImmunofluorescenceImaging analysis
This invention relates to the field of image analysis technology, specifically to a method for assessing the distribution of cardiac mesothelial cells based on immunofluorescence images. The method includes: acquiring multiple immunofluorescence images of cardiac mesothelial cells at different antibody concentrations within the assessment group; determining initial cardiac mesothelial cell regions based on the staining status of the isotype control group and the differences in staining depth among multiple staining regions in the immunofluorescence images; analyzing non-specific staining based on changes in the staining area and irregular cell boundaries of the initial cardiac mesothelial cell regions, and adjusting the antibody concentration accordingly; determining multiple target cardiac mesothelial cell regions, and obtaining the location information of the cardiac mesothelial cells based on the degree of overlap and similarity between these regions; and analyzing the spacing distribution of cardiac mesothelial cells and their distribution in the immunofluorescence images based on the location information to obtain the uniformity of the cardiac mesothelial cell distribution.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Compositions and methods for the diagnosis and treatment of retinopathies
PendingUS20260034245A1Cell receptors/surface-antigens/surface-determinantsAnimals/human peptidesHeterologousCell Surface Proteins
The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject. In particular, isolated polynucleotides and recombinant vectors encoding a particular isoform called Crumbs 1-B (CRB1-B) are provided. The CRB1-B encoding polynucleotides may be operably linked to a heterologous promoter capable of expressing the isoform in a retinal cell. Kits employing such compositions are also provided.
Owner:DUKE UNIV
Anti-FGFR2 antibodies in combination with chemotherapy agents in cancer treatment
PendingUS20260085123A1Immunoglobulins against growth factorsPharmaceutical delivery mechanismAntiendomysial antibodiesFibroblast growth factor receptor 2
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Owner:FIVE PRIME THERAPEUTICS INC
Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
PendingEP4340944A4Peptide/protein ingredientsPeptide preparation methodsDrug conjugationPharmaceutical drug
An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.
Owner:CASE WESTERN RESERVE UNIV
Method for detecting platelet stress status using kit
Provided is a method for detecting platelet stress status using a kit. The kit comprises a platelet diluent, an EAAT2 polyclonal primary antibody, a fluorescent secondary antibody for flow cytometry, an EAAT2 isotype control, a monoclonal antibody directly conjugated to a PE fluorescent dye against CD61, and 1% paraformaldehyde. The EAAT2 polyclonal primary antibody recognizes at least one of amino acid sequences as set forth in SEQ ID No. 1 to SEQ ID No. 5. The method comprises: preparing a platelet suspension using the platelet diluent; sequentially incubating the platelet suspension with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly conjugated to the PE fluorescent dye against CD61, and the fluorescent secondary antibody for flow cytometry; adding the paraformaldehyde to fix the sample to form a sample to be tested; detecting a specific signal of the sample by means of a flow cytometer; and performing statistical analysis onthe specific signal to confirm the stress status of the sample. The reagents to be used in the entire flow cytometry process are rationally proportioned to form the kit, which is conducive to standardizing the detection method.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
Anti-dr5 antibodies and methods of use thereof
PendingUS20260176368A1Hybrid immunoglobulinsPeptide/protein ingredientsAntiendomysial antibodiesCell Surface Antigens
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
Owner:GENMAB BV